Some health experts view GLP-1s as a promising option for PCOS, which lacks a standard treatment and affects millions of ...

Novo Nordisk's recent financial results and clinical progress haven't impressed Wall Street. Investors looking to strike ...

Fangzhou Inc. ("Fangzhou" or the "Company") (06086.HK), a leader in Internet healthcare solutions, signed a Memorandum of ...

Novo Nordisk sees solid Q1 results, major GLP-1 growth potential, and limited downside despite guidance cut and rising risks.

A recent spot check revealed that drugstores in Nairobi, including online pharmacies, are selling more insulin than in ...

Ozempic, a drug known for its physical health benefits, is now gaining recognition for its effectiveness in treating ...

The law firm of Kessler Topaz Meltzer & Check, LLP ( informs investors that securities class action lawsuits have been fil ...

The Delhi High Court has granted an interim injunction against Zydus Lifesciences, an Ahmedabad-based drug maker, following a ...

India's audited Pinnacle framework, with 19 million therapies and a 97% success rate, offers a scalable solution for the $9.8 ...

While the North Chicago, Illinois-based healthcare giant estimated its adjusted diluted earnings per share for Q3 could reach $1.28 - $1.32 compared to $1.33 in the consensus, its full-year outlook ...

A study reveals potentially fatal side effects of GLP-1 drugs, that people are using to lose weight. It’s well known that ...